CPP
AERI

Crow Point Partners’s Aerie Pharmaceuticals AERI Stock Holding History

Crow Point Partners’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-8,161
Closed -$241K – 142
2019
Q2 		$241K Buy
8,161
+3,684
+82% +$142K 0.04% 97
2019
Q1 		$213K Buy
+4,477
New +$197K 0.04% 109

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Crow Point Partners's AERI Position: Q3 2019 in Review

Crow Point Partners sold out of Aerie Pharmaceuticals (AERI) in Q3 2019, closing a stake of 8,161 shares — an estimated $241K sold.

Crow Point Partners first reported a position in AERI in Q1 2019 and held it in 2 quarters. The position peaked at $241K in Q2 2019. 167 funds tracked by Wall St. Rank hold AERI as of Q3 2019.

  • Crow Point Partners reported no remaining Aerie Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Crow Point Partners sold 8,161 Aerie Pharmaceuticals shares in Q3 2019, an estimated $241K.
  • Crow Point Partners first reported a position in Aerie Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • Crow Point Partners's Aerie Pharmaceuticals position peaked at $241K in Q2 2019.
  • 167 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2019.

Based on Crow Point Partners's 13F filing for Q3 2019, filed 9 Oct 2019.